Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy
Status:
Completed
Trial end date:
2018-07-27
Target enrollment:
Participant gender:
Summary
The main purpose of the investigation is to determine if curcumin reduces NF-kB DNA binding
and ultimately its downstream mediator IL-6 in patients receiving XRT for their breast cancer
after having completed chemotherapy. Patients who have received prior chemotherapy will be
eligible, because we have found that this enriched population is at particular risk for
exhibiting increased NF-kB DNA binding and IL-6 following XRT.